GLP-1 Therapies from Early Research to Clinical Evaluation

Judith Hey-Hadavi, vice president, Medical Affairs, Worldwide Clinical Trials, and Nicole Snow, senior clinical pharmacy liaison, Olympia Pharmaceuticals, discuss the transition of GLP-1 receptor agonists from clinical trials into clinical practice. They emphasize the importance of patient selection based on prior GLP-1 exposure, tolerability, and weight loss goals. Gradual dose titration is critical to minimize gastrointestinal side effects such as nausea, diarrhea, and constipation, supporting adherence and successful outcomes. The conversation highlights real-world challenges, including weight loss plateaus and the need for patient education and structured support.